Labtician Ophthalmics has officially launched Lab TRIACTIV in the Canadian market, introducing a novel artificial tear solution designed to address dry eye disease through a comprehensive triple-layer approach. The product employs advanced cationic liposomal technology to simultaneously target the lipid, aqueous, and mucin layers of the tear film.
According to the company, this multi-targeted mechanism provides sustained hydration, enhanced protection, and extended comfort while requiring fewer applications throughout the day compared to conventional artificial tears.
Triple-Layer Technology Addresses Complete Tear Film Structure
Lab TRIACTIV's formulation represents a significant advancement in dry eye management by addressing the entire tear film structure rather than focusing on a single component. The tear film consists of three distinct layers—lipid, aqueous, and mucin—each playing a crucial role in maintaining ocular surface health and comfort.
The product's key ingredients include stearylamine, cross-linked sodium hyaluronate, trehalose, and phospholipids, which work synergistically to optimize tear film stability and support overall ocular health. The cross-linked sodium hyaluronate, in particular, provides extended residence time on the ocular surface, potentially reducing the frequency of application needed for symptom relief.
Clinical Advantages and Patient Benefits
A notable feature of Lab TRIACTIV is its preservative-free formulation, which minimizes the risk of preservative-associated irritation that can exacerbate dry eye symptoms in sensitive individuals. Additionally, the product is compatible with contact lenses, addressing an important need for the significant population of dry eye sufferers who also wear contacts.
"We are incredibly proud to introduce Lab TRIACTIV to the Canadian market, reinforcing our commitment to advancing the Visual Health of Patients with solutions that make a real difference," said Polydor Strouthos, president of Labtician Ophthalmics. "Lab TRIACTIV supports our commitment to redefining industry standards. We are excited to set a new benchmark in dry eye care."
Market Context and Unmet Needs
Dry eye disease represents a significant and growing healthcare challenge, affecting millions globally with symptoms ranging from mild discomfort to severe pain and visual disturbance. Many existing treatments provide only temporary relief or target just one aspect of this multifactorial condition.
The introduction of Lab TRIACTIV comes at a time when the demand for more effective and convenient dry eye therapies continues to rise, particularly solutions that can provide longer-lasting relief with fewer daily applications. By addressing all three layers of the tear film simultaneously, Labtician Ophthalmics aims to offer a more comprehensive approach to dry eye management.
The commercial launch of Lab TRIACTIV in Canada marks the first market entry for this product, with potential for expanded availability in additional regions pending regulatory approvals.
